This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors

This study has been terminated.
(Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.)
Information provided by (Responsible Party):
Celgene Corporation Identifier:
First received: July 21, 2010
Last updated: May 25, 2016
Last verified: May 2016
What hematopoietic precursor compartments as well as hemoglobin subtypes are affected by dosing with Sotatercept (ACE-011)? Based upon a similar prior study with Procrit, Celgene has determined that all of these goals could be obtained by an intense 10 patient, Sotatercept (ACE-011) pharmacodynamic study, completed by two well known experts in the red cell production field.

Condition Intervention Phase
Solid Tumors Drug: ACE 011 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors

Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • Red Blood Cell Mass [ Time Frame: Up to One Year ]

Secondary Outcome Measures:
  • Plasma Volume [ Time Frame: Up to One Year ]
  • Absolute Reticulocyte Increase [ Time Frame: Up to One Year ]
  • Changes in Hemoglobin [ Time Frame: Up to One Year ]
  • Number of patients with adverse events [ Time Frame: Up to One Year ]

Enrollment: 4
Study Start Date: June 2010
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ACE 011 (Sotatercept)
35mg dose of ACE 011 will be given by subcutaneous injection on Day 1. Up to two additional doses of ACE 011 will be given every 42 days during the treatment period (Day 43 and Day 85)
Drug: ACE 011
35 mg subcutaneous (SC) dose on study Day 1, Day 43, Day 85
Other Name: Sotatercept


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women ≥ 18 years of age.
  2. Histologically confirmed diagnosis of a solid tumor malignancy documented by cytology or biopsy.
  3. Presence of metastatic disease.
  4. Hemoglobin value between ≥ 8.0 to < 11.0 g/dL (≥ 80 to < 110 g/L).
  5. ≥ 28 days must have elapsed (prior to pre-dose RBC mass / PV test) since previous treatment with erythropoiesis-stimulating agent (including concurrent treatment with IV iron).
  6. ≥ 28 days must have elapsed (prior to Day 1) since the last RBC blood transfusion and receipt of ≤ 2 units of blood in the past 56 days (prior to Day 1).
  7. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 1.

Exclusion Criteria:

At the time of screening, subjects who have any grade ≥ 3 toxicity (according to the currently active minor version of NCI CTCAE v4.0, except for the following disease related toxicities:

  • Hematological events - anemia, thrombocytopenia, neutropenia
  • Non-hematological events - nausea, vomiting, fatigue, muscle or bone/joint pain
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01190644

United States, Maryland
Saint Agnes Healthcare
Baltimore, Maryland, United States, 21229
Weinberg Cancer Institution at Franklin Square
Baltimore, Maryland, United States, 21237
United States, Pennsylvania
Pennsylvania Oncology
Philadelphia, Pennsylvania, United States, 19106
Sponsors and Collaborators
Celgene Corporation
Study Director: Abderrahmane Laadem, MD Celgene
  More Information

Responsible Party: Celgene Corporation Identifier: NCT01190644     History of Changes
Other Study ID Numbers: ACE-011-ST-001
Study First Received: July 21, 2010
Last Updated: May 25, 2016

Keywords provided by Celgene Corporation:
Red Blood Cell Mass
Plasma Volume
Solid Tumors processed this record on September 21, 2017